Cumberland Pharmaceuticals (NASDAQ:CPIX) Shares Cross Above 200 Day Moving Average – Time to Sell?

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $3.33 and traded as high as $3.86. Cumberland Pharmaceuticals shares last traded at $3.59, with a volume of 193,907 shares trading hands.

Analysts Set New Price Targets

A number of research analysts have weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a research note on Monday, December 29th. Wall Street Zen upgraded Cumberland Pharmaceuticals to a “hold” rating in a report on Saturday, January 10th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Cumberland Pharmaceuticals currently has a consensus rating of “Sell”.

Cumberland Pharmaceuticals Stock Performance

The stock has a 50 day moving average of $3.81 and a 200 day moving average of $3.34. The company has a quick ratio of 1.11, a current ratio of 1.23 and a debt-to-equity ratio of 0.20. The firm has a market cap of $58.49 million, a price-to-earnings ratio of -16.29 and a beta of -0.52.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last issued its quarterly earnings results on Tuesday, November 4th. The specialty pharmaceutical company reported ($0.06) earnings per share for the quarter. The firm had revenue of $8.29 million for the quarter. Cumberland Pharmaceuticals had a positive return on equity of 5.13% and a negative net margin of 8.06%.

Institutional Investors Weigh In On Cumberland Pharmaceuticals

A number of large investors have recently modified their holdings of CPIX. XTX Topco Ltd acquired a new position in shares of Cumberland Pharmaceuticals during the 2nd quarter worth $34,000. Heron Bay Capital Management acquired a new position in Cumberland Pharmaceuticals during the second quarter worth about $111,000. Two Sigma Investments LP raised its stake in Cumberland Pharmaceuticals by 16.5% during the third quarter. Two Sigma Investments LP now owns 37,591 shares of the specialty pharmaceutical company’s stock worth $117,000 after acquiring an additional 5,326 shares in the last quarter. Bridgeway Capital Management LLC lifted its holdings in shares of Cumberland Pharmaceuticals by 2.3% in the second quarter. Bridgeway Capital Management LLC now owns 188,355 shares of the specialty pharmaceutical company’s stock worth $631,000 after acquiring an additional 4,200 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Cumberland Pharmaceuticals by 11.1% in the 3rd quarter. Dimensional Fund Advisors LP now owns 280,869 shares of the specialty pharmaceutical company’s stock valued at $876,000 after purchasing an additional 27,980 shares in the last quarter. Institutional investors and hedge funds own 15.51% of the company’s stock.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland’s strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.

The company’s flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.